Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) dropped 4.4% during mid-day trading on Wednesday . The company traded as low as $18.37 and last traded at $18.59, with a volume of 217,278 shares. The stock had previously closed at $19.45.

AMPH has been the topic of a number of analyst reports. BMO Capital Markets initiated coverage on Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They set a “market perform” rating and a $17.00 price target on the stock. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Monday, August 1st. Needham & Company LLC reduced their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. Piper Jaffray Cos. reissued an “overweight” rating and set a $22.00 price target on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 11th. Finally, Jefferies Group increased their price target on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Buy” and an average target price of $19.83.

The firm’s 50 day moving average price is $17.87 and its 200 day moving average price is $14.64. The firm has a market cap of $844.21 million and a PE ratio of 60.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.22. During the same quarter in the previous year, the firm earned ($0.09) EPS. The business earned $68 million during the quarter, compared to analysts’ expectations of $62.10 million. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. On average, analysts expect that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current year.

In related news, CFO William J. Peters sold 2,297 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $17.76, for a total value of $40,794.72. Following the sale, the chief financial officer now owns 64,652 shares of the company’s stock, valued at approximately $1,148,219.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jason B. Shandell sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $19.95, for a total transaction of $199,500.00. Following the completion of the sale, the general counsel now directly owns 212,961 shares in the company, valued at approximately $4,248,571.95. The disclosure for this sale can be found here.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.